

AMENDMENTS TO THE CLAIMS

Please further amend the claims as follows (a listing of the amendments cumulative to date is provided at pages 10-17 of this Response):

2. (amended) [An] A purified antibody [according to claim 1 which is mouse monoclonal antibody 33.28 (ATCC HB-12315) or an antibody which binds specifically to a colon carcinoma-associated epitope that specifically binds to monoclonal antibody 3328] which competitively inhibits binding of the antibody of claim 1 to the human colon carcinoma - associated protein antigen.

3. (amended) An antibody according to claim 2 wherein said colon carcinoma-associated antigen is a protein having a molecular weight of about 61.1 kilodaltons as measured by gradient polyacrylamide gel electrophoresis.

5. (amended) [An] A purified antibody [according to claim 4 wherein said colon carcinoma-associated antigen is a protein having a molecular weight of about 72 kilodaltons] which competitively inhibits binding of the antibody of claim 4 to the human colon carcinoma - associated protein antigen.

6. (amended) An antibody according to claim [2] 5 wherein said colon carcinoma-associated antigen is a glycoprotein, the protein component having a molecular weight of [61.1] about 72 kilodaltons as measured by gradient polyacrylamide gel electrophoresis.

44. (amended) The chimeric antibody according to claim [42] 43 wherein said colon carcinoma-associated antigen is a protein having a molecular weight of 72 [kilodalton] kilodaltons as measured by gradient polyacrylamide gel electrophoresis.

51. (new) A purified antibody which is raised against an immunopurified human colon carcinoma associated antigen that is specifically bound by monoclonal antibody 31.1 , as

produced by hybridoma PCA 31.1, deposited with the American Type Culture Collection and assigned accession number PTA-2497.